AxoGen (AXGN) Competitors

National Vision (NASDAQ:EYE) and AxoGen (NASDAQ:AXGN) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Which has stronger earnings and valuation, EYE or AXGN?

AxoGen has lower revenue, but higher earnings than National Vision. AxoGen is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Vision	$1.82B	1.05	-$28.50M	-$0.33	-73.36
AxoGen	$187.34M	3.08	-$9.96M	-$0.15	-84.47

Does the media refer more to EYE or AXGN?

In the previous week, National Vision had 6 more articles in the media than AxoGen. MarketBeat recorded 13 mentions for National Vision and 7 mentions for AxoGen. National Vision's average media sentiment score of 1.20 beat AxoGen's score of 0.47 indicating that National Vision is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Vision	5 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, EYE or AXGN?

National Vision has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Do analysts recommend EYE or AXGN?

National Vision currently has a consensus price target of $24.18, indicating a potential downside of 0.12%. AxoGen has a consensus price target of $24.50, indicating a potential upside of 93.37%. Given AxoGen's stronger consensus rating and higher probable upside, analysts clearly believe AxoGen is more favorable than National Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Vision	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
AxoGen	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders have more ownership in EYE or AXGN?

80.3% of AxoGen shares are held by institutional investors. 2.7% of National Vision shares are held by company insiders. Comparatively, 2.8% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is EYE or AXGN more profitable?

National Vision has a net margin of -1.40% compared to AxoGen's net margin of -3.68%. National Vision's return on equity of 3.44% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Vision	-1.40%	3.44%	1.40%
AxoGen	-3.68%	-7.09%	-3.67%

Summary

National Vision beats AxoGen on 9 of the 16 factors compared between the two stocks.